With Neil Woodford’s future uncertain, is this a good time to buy shares of Woodford Patient Capital Trust?

Would the departure of Woodford be a signal to buy? Studies show that the leaving of poor managers leads to a return to the performance of fund shares.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Following the recent debacle, coupled with poor performances, Woodford Patient Capital Trust (LSE: WPCT) shares have lost around 25% in the last three weeks alone.

Unlike Neil Woodford’s Equity Income fund, which was closed to new investments and withdrawals and lost 20% in value in June, his investment trust (Patient Capital) cannot have the same fate.

Closed-end funds are immune to withdrawals

Woodford Patient Capital Trust is a closed-end fund where funds are raised at inception with shares’ issuance as in an IPO. Like a company’s shares, closed-end funds trade on the stock market and Patient Capital is currently trading on the FTSE 350.

The valuation of closed-end funds is tangible and follows the value of their assets while the prices of their share is more volatile. Today, Patient Capital is trading at around 63p to £1, representing a 37% discount on its valuation.

The launch of Woodford’s personal fund in 2015 with great fanfare was a success, and attracted at its peak £15bn of investor money in 2017. The loss of confidence following poor performance and large investors withdrawals led to a decline in the fund’s shares.

Woodford is expected to leave, but what happens next?

Neil Woodford was a star manager at Invesco for 25 years, surpassing benchmark indices and surviving the dot.com bubble and the subprime crash.

Its recent poor performance and the subsequent closure of its equity income fund have forced Patient Capital’s board, in consultation with its broker Winterflood Securities, to consider Woodford’s departure. But what happens when a poor manager leaves a fund?

Depending on new hires and the reorganisation of the management team, Patient Capital – while keeping the same name – can be considered as a brand-new fund.

A revival for Patient Capital shares?

Usually, when star managers leave a fund, a massive withdrawal of investors follows, and the subsequent performance of the fund decreases. Famous examples include the departure of Richard Buxton from Schroders, which caused an exodus of £3.35bn.

But when poor performers leave the fund, the opposite also happens.

This chart (source: Adviser Investments) shows what happened to Vanguard Capital Opportunity Fund performance following a management change (indicated by the red dot) in 1998. Other empirical studies conducted by researchers at CASS Business School show that UK funds improve their performance after the departure of a poor manager by successfully reorganising the management team.

A good buy?

The current discount on the NAV makes an investment in Patient Capital a bargain, in my opinion. Bargain hunters could start buying at these levels and the planned changes at the head of the fund might make it more attractive to returning institutional investors.

Neil Woodford was a cheap manager because his fees were linked to his performance. On the downside, a new management could change the fee structure and make it fixed, but this could be easily compensated by the recovery in performance.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jean-Philippe has no position in any company listed here. The Motley Fool UK has recommended Woodford Patient Capital. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »